Groowe Groowe / Newsroom / INCY
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

INCY News

Incyte Genomics Inc

Vitiligo Treatment Market Report 2026 - Global Industry Size, Share, Trends, Opportunity, and Forecast to 2031

globenewswire.com
INCY

Molecular Switch Targeting Therapies Market Research Report 2026: Opportunities in Targeted Drug Delivery Systems and Therapies in Oncology, Autoimmune, Inflammatory, and Neurological Disorders

globenewswire.com
MRK BMY AZN PFE NVS LLY GILD JNJ REGN ABBV NVO SNY VRTX AMGN BIIB INCY EXEL SRPT CRSP EDIT NTLA ALNY MRNA BNTX COHR IMUX INSM CYTK KODK LULU NVDA GOOG MSFT IBM AMAT ILMN ALKS ACAD MNKD TEVA BHC XBI IBB XLF XLK XLV JAZZ ACGL

House Dust Mite Disease Market to Exhibit Substantial Growth at a CAGR of 3.5% During the Forecast Period (2025-2034) | DelveInsight USA - English USA - English

prnewswire.com
ALKS STG GSK SNY TEVA AZN INCY REGN PFE BMY LLY AMGN ABBV GILD BIIB CSL VRTX BHC NVS MRK LEO ALLT CNTB INM

Psoriasis Market to Exhibit Growth at a CAGR of 1.7% During the Forecast Period (2025-2034), Owing to Continuous Innovation in Biologic Therapies and Approval of Oral Small Molecules | DelveInsight

prnewswire.com
TAK JNJ CANF AMGN ABBV NVS BMY AZN BHC LLY UCB LEO REGN XBI IBB JAZZ MRK SNY GILD INCY PFE LULU PRTH DRH BIIB TEVA ARCT HRMY CRSP NTLA EDIT SNOW DDOG CRM GOOG MSFT AAPL AMZN TSLA NVDA META NFLX DIS CMCSA VZ T KO PEP MCD SBUX HD EXAS ILMN BNTX MRNA XOM CVX BA CAT GE IBM INTC CSCO ADBE QCOM AMAT MU ORCL ACN COST WMT TGT LOW HON GD LMT RTX BAX

Immuno-Oncology Drugs Market Projected to Reach US$ 185.69 Billion by 2035 | Astute Analytica

globenewswire.com
VRTX MRK BMY GILD JNJ AZN NVS REGN AMGN PFE BIIB ISRG MDLZ IMCR CRSP EDIT NCLH ACRS ALNY INCY ABBV LULU EXAS RDVY ONCY GENM DTIL XAIR CGEN ADPT ATRC CODX CORT CRBU CTAS CYTK DASH DECK DOCU EBAY ELAN ENPH EPAM FIVN FORM FTNT GDRX GEHC GNTX GOOS GRMN GTLB HGV HLT HOLX HON HPE HPQ HRB HSIC HWM IDXX ILMN INSM INTC INTU IRTC ITRI IVZ JBL JEF JHG JLL JPM KDP KHC KODK LAKE LCID LRCX LSCC LYFT MCHP MELI MGM MKTX MLCO MNST MRVL MTCH MU NDSN NEO NET NFLX NKE NOC NOW NRG NTAP NTES NVDA NXPI ODFL OMC ON ORCL ORLY OSK OTIS OXY PANW PAYX PCAR PCG PDD PEP PGR PH PHG PII PKX PLAB PLD PLUG PM PNW POOL POST PPG PPL PRGS PRGO PRLB PRO PRTA PSFE PSNY PTC PVH QCOM QGEN QRVO RBLX RCL RDNT REI REIT RF RGEN RIVN RL RMBS RMD ROBT ROKU ROST RPRX RS RSG RSP RVSN RYAAY S SABR SAN SAVA SBAC SBRA SBUX SCHD SCL SD SE SEDG SEE SEIC SELF SEM SIRI SJM SKX SLB SLGN SMCI SMLR SNBR SNOW SNPS SO SONO SPCE SPGI SPNS SQM SRPT SSNC ST STAG STLD STNG STOK STX SUN SWKS SYK SYY T TAL TAN TCOM TDOC TECK TEF TEK TEL TER TFX TGT TGTX THC THO TIGR TITN TJX TLRY TMO TMUS TNDM TNET TOL TOPS TORO TPH TPL TQQQ TR TRC TRIP TRMB TRMK TRN TRP TRT TRVG TS TSCO TSE TSLA TSN TT TTC TTD TTI TTNP TTWO TU TUSK TV TVC TVE TW TWLO TX TXN TXRH TXT TYL U UAL UBER UDR UEC UHAL ULTA UMC UMH UNFI UNH UNIT UNM UPST URBN USA USFD USNA USPH UTHR V VRSK VTR VTRS VZ W WAB WDC WEC WELL WEN WERN WEX WFC WGO WHD WHR WIA WMB WMT WNS WPC WRB WST WTAI WTFC WTS WU WY WYNN XBIT XCUR XENE XFLT XGN XHR XLP XOM XPO XRAY XRT XTLB XXII XYL YETI YMM YPF YUM Z ZBRA ZCMD ZIM ZION ZKIN ZNTL ZTO ZTS ZYME

Incyte annuncia i primi risultati positivi dallo studio pivotale di Tafasitamab (Monjuvi ® /Minjuvi ®) come trattamento di prima linea per il linfoma diffuso a grandi cellule B

businesswire.com
INCY

Incyte gibt positive Topline-Ergebnisse der Zulassungsstudie zu Tafasitamab (Monjuvi ® /Minjuvi ®) als Erstlinienbehandlung für das diffus großzellige B-Zell-Lymphom bekannt

businesswire.com
INCY

Incyte annonce des résultats positifs de l'étude pivot évaluant le tafasitamab (Monjuvi ®/Minjuvi ®) en tant que traitement de première intention contre le lymphome diffus à grandes cellules B

businesswire.com
INCY

Incyte maakt positieve resultaten bekend van cruciaal onderzoek naar tafasitamab (Monjuvi ® /Minjuvi ®) als eerstelijnsbehandeling voor diffuus grootcellig B-cellymfoom

businesswire.com
INCY

Incyte anuncia resultados positivos del estudio pivotal de tafasitamab (Monjuvi ®/Minjuvi ®) en el tratamiento de primera línea del linfoma difuso de células B grandes

businesswire.com
INCY